Clinical trial · Observational
AI-Powered Precision Decision-Making for Pancreatic Diseases
A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery/treatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Pancreatitis (AP) | — | UNRESOLVED | — |
| Chronic Pancreatitis | — | UNRESOLVED | — |
| Diagnose Disease | — | UNRESOLVED | — |
| IPMN, Pancreatic | Pancreatic Intraductal Papillary Mucinous Neoplasm | ALIAS | 0.90 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Pancreatic Cystic Lesions | — | UNRESOLVED | — |
| Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnosis by Artificial Intelligence model | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- AI group
- description
- Diagnosis by Artificial Intelligence model
- interventionNames
- Diagnostic Test: Diagnosis by Artificial Intelligence model
- label
- Clinicians group
- description
- Diagnosis by clinicians
Primary outcomes (1)
- measure
- Classification accuracy
- timeFrame
- From date of contrast-enhanced CT scan to 1 year
- description
- The percentage of cases correctly classified by AI out of the total number of cases.
Secondary outcomes (3)
- measure
- Agreement rate with clinical decisions
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically suspected pancreatic disease. * Scheduled to undergo contrast-enhanced CT. * Signed informed consent form indicating agreement to participate. Exclusion Criteria: * History of pancreatic surgery. * Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal/hepatic dysfunction. * Suboptimal image quality affecting diagnosis. * Concurrent participation in another interventional clinical trial. * Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.
References
Publications (0)
Data not yet available